ResMed (RMD) Reports In-Line Q1 EPS, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $240.51 +5.91%
Financial Fact:
Other, net (note 12): 1.27M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Other, net (note 12): 1.27M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q1 EPS of $0.66, in-line with the analyst estimate of $0.66. Revenue for the quarter came in at $523.7 million versus the consensus estimate of $505.61 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- NewLake Capital Partners, Inc. (NLCP) Misses Q2 EPS by 9c
- NewAmsterdam Pharma Company N.V. (NAMS) Tops Q3 EPS by 35c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
